IP Library Granted Patent US 8,541,553
Granted Patent B2
US 8,541,553 · App. 12/601,780 · Granted Sep 24, 2013

Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,553
App. No.
12/601,780
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

Claims (2)

1. An antibody characterized in that it is produced by the hybridoma cell line having DSMZ accession number DSM ACC2879.

2. A hybridoma cell line having DSMZ accession number DSM ACC2879.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2013
From: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
To: BAXTER HEALTHCARE SA
Reel/Frame 030034/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2011
From: HUMER, JOHANNES; MAYER, BERND; MUSTER, THOMAS; WALTENBERGER, ANDREA
To: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
Reel/Frame 025741/0412 →